RecruitingNCT06849180

Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data

Studying Carcinoma of liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhongda Hospital
Principal Investigator
Gao-Jun Teng, M.D
Zhongda hospital, Southeast university, Nanjing, China
Intervention
Interventional therapies combined with or without systemic drugs(combination_product)
Enrollment
198 enrolled
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Eastern Hepatobiliary Surgery Hospital · The First Affiliated Hospital of Zhengzhou University · Jiangsu Cancer Institute & Hospital · Yunnan Cancer Hospital · Zhejiang Cancer Hospital · Shanghai Zhongshan Hospital · Sun Yat-Sen University Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06849180 on ClinicalTrials.gov

Other trials for Carcinoma of liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of liver and intrahepatic biliary tract

← Back to all trials